CSL (ASX: CSL) shares jumped 5.7% to A$97.91 on Friday, its strongest one-day gain since February 2022.
The move came as investors rotated back into ASX healthcare stocks after a painful year for the sector.
CSL is still down almost 60% over the past year, so one strong day does not prove the recovery has started.
The company is dealing with profit pressure, leadership change, restructuring and major write-downs.
For now, investors may want to wait for stronger evidence before calling the bottom.
CSL shares jump as healthcare comes back to life
CSL (ASX: CSL) finally gave investors something to cheer about on Friday. The stock rose 5.7% to A$97.91, making it one of the strongest performers in the ASX 300.
But this was not just a CSL story. It was a healthcare story.
The ASX healthcare sector rose about 3.5%, while the materials sector fell around 2.3%. That shows investors were moving money out of miners and back into beaten-down defensive growth stocks.
CSL was not alone. Cochlear, ResMed, Pro Medicus and Telix Pharmaceuticals also rose strongly. When several major healthcare names jump together, it often means investors are buying the whole sector, not just one company.
That is why investors should be careful before reading too much into CSL’s one-day rally.
Why investors came back to healthcare
ASX healthcare stocks have had a very rough run. The sector had fallen sharply over the past year, while mining stocks had performed much better.
When one sector becomes deeply oversold and another becomes crowded, money can quickly rotate. That appears to be what happened on Friday.
Investors may also be looking for value. CSL used to be one of the ASX’s most trusted blue-chip growth stocks. After a huge fall in the share price, some buyers may now believe the bad news is already priced in.
That may be true, but it is not guaranteed.
Why CSL fell so hard
CSL’s share price fall has been building for some time.
In 2025, the company announced a major restructure, including plans to separate its Seqirus vaccine business into a standalone ASX-listed company. It also moved to cut costs and simplify the group.
Then came more pressure. CSL faced weaker earnings expectations, lower confidence in parts of the business and concerns around its Vifor acquisition. In May 2026, the company said it expected to recognise around US$5 billion of additional non-cash pre-tax impairments across FY26 and FY27.
That was a major hit to investor confidence.
CSL also lowered its FY26 expectations, with revenue now expected to be around US$15.2 billion and NPATA around US$3.1 billion, before restructuring and impairment costs.
For a company that once traded like a reliable compounder, that was a big reset.
Is CSL still a quality business?
Yes, CSL is still a high-quality healthcare company.
Its plasma business remains very hard to copy. It has a global scale, deep manufacturing expertise and long-standing relationships across healthcare markets. These are real advantages.
But quality alone is not enough. Investors also need earnings growth, confidence in management and a clear path back to stronger margins.
That is where the market still needs proof.
Should investors buy CSL now?
CSL’s 5.7% jump is encouraging, but it does not prove the bottom is in.
The share price is still down heavily over the past year, and the company is still working through a difficult reset. A short-term bounce can happen even when a business is still facing real challenges.
For long-term investors, CSL may now be worth watching closely. The valuation is much lower than it used to be, and the core business still has strengths.
But for cautious investors, waiting may be the better move. The next full-year result will be important. Investors need to see whether CSL can stabilise earnings, control costs and rebuild trust.
Bottom line
CSL’s rebound was a welcome sign for ASX healthcare investors, but it is too early to call it a full recovery.
The business is not broken, but confidence has been badly damaged. Until CSL proves the turnaround is working, the stock remains a recovery play rather than a clear buy.
For now, the smarter move may be to watch the next results closely and see whether Friday’s bounce can turn into a sustained recovery.
